{ }
001122334455554433221100
001122334455554433221100

halozyme withdraws evotec buyout bid following lack of interest

Halozyme has withdrawn its bid to acquire Evotec after the latter showed no interest in negotiations, despite a proposed valuation of €2 billion. Meanwhile, Neurogene reported the death of a patient in a gene therapy trial for Rett syndrome, linked to known risks of the treatment. In other news, Argenx is advancing its drug efgartigimod for myositis, while Kyowa Kirin has agreed to pay Kura Oncology $330 million for rights to an experimental leukemia drug.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.